NCT02527746 2024-02-23
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 1 Completed
EVIVE Biotechnology
Institut de cancérologie Strasbourg Europe
The First Affiliated Hospital with Nanjing Medical University
TTY Biopharm
AstraZeneca
GBG Forschungs GmbH
GBG Forschungs GmbH
Shandong Cancer Hospital and Institute
King Faisal Specialist Hospital & Research Center